NLS Pharmaceutics announced that the Israeli Patent Office has granted approval for Patent Application 261418, which covers Mazindol as a method of treatment for Attention Deficit/Hyperactivity Disorder. This patent is expected to expire no earlier than 2037.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NLSP:
- NLS Pharmaceutics closes initial tranche of $10M purchase agreement
- NLS Pharmaceutics upgraded to Buy from Hold at Maxim
- NLS Pharmaceutics announces purchase agreement with BVF Partners
- NLS Pharmaceutics receives Nasdaq minimum bid price notification
- NLS Pharmaceutics announces notice of allowance for U.S. patent on Mazindol